↓ Skip to Main Content

the new generation glocalized patient network in theragenomic and personalized medicine and individualized drug safety

search: thasso

Search for:

Log in

Main Navigation

english
thasso
thasso post
thasso community
thasso toolbox
thasso academy
thasso – about
donations $
Cookie Policy (EU)

Home › Posts tagged Trametinib [Mekinist]

Tag: Trametinib [Mekinist]

Dabrafenib/Trametinib-Combo approved for BRAF-positive anaplastic thyroid cancer

By Joseph Gut - thasso Posted on May 5, 2018 Posted in Allelic Variant, New Drug Approval, New Indication Approval, Personalized Medicine, Regulatory Announcement, Targeted Therapy, Thasso Post, Theragenomic Medicine 1 Comment Tagged with Anaplastic Thyroid Cancer (ATC), BRAF Gene, BRAF V600E Allelic Variant, BRAF V600E Positive], Dabrafenib (Tafinlar), Metatstatic Melanoma, Thasso Post, Theragenomic Medicine, Thyroid Cancer, Trametinib [Mekinist]

Dabrafenib/Trametinib-Combo approved for BRAF-positive anaplastic thyroid cancer

May 05, 2018 – The American Food and Drug Administration (FDA) just approved the combination of Dabrafenib (Tafinlar)/Trametinib (Mekinist) to be administered together for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has …

Dabrafenib/Trametinib-Combo approved for BRAF-positive anaplastic thyroid cancer Read more »

European Medicines Agency (EMA) recommends approval of Trametinib [Mekinist] for the treatment of melanoma with a BRAF V600E mutation

By Joseph Gut - thasso Posted on May 1, 2014 Posted in Personalized Medicine, Targeted Therapy, Thasso Post, Theragenomics No Comments Tagged with BRAF V600E Mutation, European Medicines Agency (EMA), MEK Protein Kinase, Melanoma [Metastatic], Melanoma [Unresectable], Thasso Post, Trametinib [Mekinist]

April 30, 2014 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Mekinist (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E mutation. Mekinist …

European Medicines Agency (EMA) recommends approval of Trametinib [Mekinist] for the treatment of melanoma with a BRAF V600E mutation Read more »

Dabrafenib [Tafinalar] and Trametinib [Mekinist] Approved for BRAF V600 Mutated Metastatic Melanoma

By Joseph Gut - thasso Posted on May 30, 2013 Posted in Allelische Variante, Genetic Predisposition, New Drug Approval, Personalized Medicine, Pharmacogenetics, Thasso Post No Comments Tagged with BRAF V600E Positive], BRAF V600K Positive, Companion Test, Dabrafenib [Tafinalar], Melanoma [Metastatic], Theragenomic Medicine, Trametinib [Mekinist], Vemurafenib [Zelboraf]

May 30, 2013 – From a Medscape News Release we learn today that two new drugs have been approved by the US Food and Drug Administration (FDA) for use in certain patients with metastatic or unresectable melanoma, along with a …

Dabrafenib [Tafinalar] and Trametinib [Mekinist] Approved for BRAF V600 Mutated Metastatic Melanoma Read more »

Optional: Social Subscribe/Login

thasso: donate

We need your help. Please support the development of thasso through donations. Thank you. Nous avons besoin de votre aide. S'il vous plaît, vous pouvez soutenir le développement de thasso grâce à des dons. Merci. Wir brauchen Ihre Hilfe. Bitte unterstützen Sie die Entwicklung von thasso durch Spenden. Vielen Dank.

thasso: conditions

thasso: newest tweets

Tweets by thasso_info

FDA press releases

FDA Roundup: July 1, 2022 July 1, 2022
FDA Infant Formula Update: June 30, 2022 June 30, 2022
Coronavirus (COVID-19) Update: FDA Recommends Inclusion of Omicron BA.4/5 Component for COVID-19 Vaccine Booster Doses June 30, 2022
FDA Roundup: June 28, 2022 June 28, 2022
FDA Infant Formula Update: June 28, 2022 June 28, 2022

FDA MedWatch

Information Regarding Medically Necessary Specialty Infant Formulas: Notice to Health Care Providers July 1, 2022
Use Duodenoscopes with Innovative Designs to Enhance Safety: FDA Safety Communication June 30, 2022
2022 Safety Communications June 30, 2022
Loud Muscle Science, LLC Issues Voluntary Recall of Launch Sequence Capsules Due to the Presence of Undeclared Tadalafil in United States and Canada June 30, 2022
Update: Mammography Problems at Capitol Radiology, LLC, doing business as Laurel Radiology Services in Laurel, Maryland: FDA Safety Communication June 30, 2022

EMA Press releases

Global regulators agree on key principles on adapting vaccines to tackle virus variants, , 01/07/2022 July 1, 2022
Assessing dietary exposure to residues of veterinary medicines, feed additives and pesticides in food of animal origin in the EU, CVMP, 30/06/2022 June 30, 2022
Call for companies to register their Industry Single Point of Contact (i-SPOC) on supply and availability, , 28/06/2022 June 28, 2022
Monkeypox: EMA starts review for Imvanex, CHMP, 28/06/2022 June 28, 2022
Hydroxyethyl-starch solutions for infusion recommended for suspension from the market, CMDh, 25/02/2022 June 27, 2022

random genetics

When ASD occurs with intellectual disability, a convergent mechanism for two top-ranking risk genes may be the cause July 1, 2022
University at Buffalo scientists have discovered a convergent mechanism that may be responsible for how two top-ranked genetic risk factors for autism spectrum disorder/intellectual disability (ASD/ID) lead to these neurodevelopmental disorders.
New classification system proposed for colorectal cancer to guide treatment and clinical trials July 1, 2022
A team of clinician-scientists and scientists, led by the National Cancer Centre Singapore (NCCS) and A*STAR's Genome Institute of Singapore (GIS) together with collaborators in Europe and South Korea, used single cell techniques to uncover a central dichotomy for colorectal cancer cells, leading to a proposed update of the classification system for the disease. These […]
Study shows HIV speeds up body's aging processes soon after infection June 30, 2022
HIV has an "early and substantial" impact on aging in infected people, accelerating biological changes in the body associated with normal aging within just two to three years of infection, according to a study by UCLA researchers and colleagues.
Scientists discover link between genetics and failure of joint replacements June 30, 2022
Scientists from leading biotech company ExplantLab in Newcastle (UK) have discovered a genetic link to explain why some patients develop pain and early failure of joint replacements.
Novel gene for Alzheimer's disease in women identified June 30, 2022
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia, affecting more than 5.8 million individuals in the U.S. Scientists have discovered some genetic variants that increase the risk for developing Alzheimer's; the most well-known of these for people over the age of 65 is the APOE ε4 allele. Approximately […]

Recent Comments

David Walliams on Is genetic testing of value for ALS patients?: “CURED FROM GENITAL HERPES More than 5 years ago I was in pain with this deadly herpes virus, A few…” Nov 7, 16:08
Raul Malkovic on Is genetic testing of value for ALS patients?: “HOW MY WIFE GOT CURED FROM ALS Below is how i got a cure for my wife who suffered from Amyotrophic Lateral Sclerosis…” Nov 6, 21:18
Pamela Erickson on Is genetic testing of value for ALS patients?: “My husband was diagnosed with ALS (amyotrophic lateral sclerosis) when he was 63 years old 4 years ago. The Rilutek…” Aug 13, 13:04
thassodotcom on Unlucky women with BIA-ALCL: An update: “The Therapeutic Goods Agency (TGA) of Australia has just issued a hazard alert concerning the risk of breast implant-associated anaplastic…” Aug 4, 09:17
thassodotcom on Tofacitinib (Xeljanz): Dangers of blood clots in the lungs and of death: “According to its Drug Safety Communication from 07/26/2019, the FDA has approved new warnings about an increased risk of blood…” Aug 4, 08:40

Tag Cloud

Adverse Drug Reaction (ADR) African American Allelic Variant American Food & Drug Administration (FDA) American Food & Drug Administration (FDA) Boxed Warning Breast Cancer Canagliflozin (Invokana) Cancer Children Committee for Medicinal Products for Human Use (CHMP) Companion Test Covid-19 Disease Diabetes Empagliflozin [Jardiance] Epidermal Growth Factor Receptor (EGFR) Erectile Dysfunction Ethnicity European Medicine Agency (EMA) European Medicines Agency (EMA) Food and Drug Administration (FDA) Gene Therapy Genetic Background Genetic Predisposition Genetic Testing Health Canada Non-Small Cell Lung Cancer (NSCLC) Pembrolizumab [Keytruda] Personalized Medicine Phenotype Progressive Multifocal Leukoencephalopathy (PML) Rare Disease Risk Evaluation and Mitigation Strategy (REMS) SARS-CoV-2 Schizophrenia Sildenafil [Viagra] Sodium-Glucose Cotransporter-2 (SGLT2) Stevens Johnson Syndrome [SJS] Targeted Therapy ThassoBase Thasso Post Theragenomic Medicine Toxic Epidermal Necrolysis (TEN) Type 2 Diabetes Vemurafenib [Zelboraf]

thasso

thasso, the new generation glocalized patient network in theragenomic and personalized medicine and individualized drug safety provides access to and sharing of personal and professional information in health and disease to individual patients, to patient subgroups, and to large patient populations worldwide

keys

Social Media, Social Network, Theragenomic Medicine, Social Medicine, Personalized Medicine, Genomic Medicine, Participative Medicine, Targeted Therapy, Individualized Therapy, Personalized Therapy, Individualized Drug Safety, Personalized Drug Safety, Genetic Variants, Allelic Variants, Genotypes, Molecular Phenotypes, Clinical Phenotypes, Companion Test, Heart Disease, Arthritis, Asthma, Diabetes, Hypertension, Malignant Tumors, Breast Cancer, Lung Cancer, Skin Cancer, Erectile Dysfunction, Crowd Sourcing, Patient Sourcing, Participative Sourcing, Collective Experience, Collective Community Wisdom, Apomediary Patient Expert, Patient Cloud,

meta

Register
Log in
Entries feed
Comments feed
WordPress.org

© 2022 thasso | Powered by Responsive Theme

Manage Cookie Consent

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options Manage services Manage vendors Read more about these purposes

View preferences

{title} {title} {title}